The 3rd International Workshop on Acute Leukemias (iwAL) 2021 took place on 28-30 April with VJHemOnc as official media partner. The workshop featured a global expert faculty, sharing the latest advances in acute leukemia through insightful presentations and live interactive panel discussions.

On-demand presentations and panel discussions with leading experts are now available to watch below.

Session topics include:
B- & T-ALL, MRD & Diagnostics, Immunotherapies, When to Place CAR-T in the Clinical Routine, Advances in AML biology, Controversies in AML, ASCT and post-ASCT Maintenance Approaches, MDS New Data/Novel Therapies, Mechanisms of Drug Resistance, To Target or Not in Elderly AML, Emerging Therapies in AML

iwAL 2021

iwAL 2021

The 3rd International Workshop on Acute Leukemias (iwAL) 2021 took place on 28-30 April with VJHemOnc as official media partner. The workshop featured a global expert faculty, sharing the latest advances in acute leukemia through insightful presentations and live interactive panel discussions.

On-demand presentations and panel discussions with leading experts are now available to watch below.

Session topics include:
B- & T-ALL, MRD & Diagnostics, Immunotherapies, When to Place CAR-T in the Clinical Routine, Advances in AML biology, Controversies in AML, ASCT and post-ASCT Maintenance Approaches, MDS New Data/Novel Therapies, Mechanisms of Drug Resistance, To Target or Not in Elderly AML, Emerging Therapies in AML

Session 1: Advances in T-ALL
Jan Cools
Update in T-ALL biology
Jan Cools VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium
Jonathan Bond
Prognostic impact of T-ALL subtype
Jonathan Bond University College Dublin, Dublin, Ireland
He Huang
CAR T-cells for T-ALL?
He Huang Zhejiang University, Hangzhou, China
Stuart Winter
COG AALL0434 in newly diagnosed t-cell ALL
Stuart Winter Children's Minnesota, Minneapolis, MN, United States
Session 1 panel discussion
Session 2: B-ALL
Charles  Mullighan
Scientific update in B-ALL
Charles Mullighan St. Jude Children’s Research Hospital, Memphis, TN, United States
Patrick Brown
Blinatumomab in frontline pediatric ALL
Patrick Brown Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, United States
Jeffrey Rubnitz
Venetoclax plus navitoclax for ALL
Jeffrey Rubnitz St. Jude Children's Research Hospital, Memphis, TN, United States
Nora Zieger
Reducing T-cell exhaustion with CD19/CD3 BiTEs
Nora Zieger Ludwig Maximilian University of Munich, Munich, Germany
Session 2 panel discussion
Session 3: MRD & Diagnostics
Mignon Loh
Stratifying risk with MRD in ALL
Mignon Loh University of California San Francisco, San Francisco, CA, United States
Janine Stutterheim
MRD in infant ALL
Janine Stutterheim Princess Máxima Center, Utrecht, Netherlands
Session 3 panel discussion
Session 4: ALL Immunotherapies
Elias  Jabbour
R/R ALL: BLINA or INO first? Which combinations? - Blinatumomab
Elias Jabbour University of Texas MD Anderson Cancer Center, Houston, TX, United States
Nicola  Gökbuget
R/R ALL: BLINA or INO first? Which combinations? - Inotuzumab
Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany
Session 4 panel discussion
Session 5: When to Place CAR-T in the Clinical Routine?
Jordan Gauthier
Managing toxicities in CAR T-cell ALL patients
Jordan Gauthier Fred Hutchinson Cancer Research Center, Seattle, WA, United States
Daniel Lee
CAR T-cell therapy followed by transplant in children/YAs
Daniel Lee University of Virginia, Charlottesville, VA, United States
Peihua Lu
A Synthetic T-Cell & Antigen Receptor (STAR) therapy for R/R B-ALL
Peihua Lu Lu Daopei Hospital, Beijing, China
Session 5 panel discussion
Session 6: Advances in AML Biology
Koichi Takahashi
Single cell genomics and AML
Koichi Takahashi The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Ravindra  Majeti
Stem Cells in Human AML
Ravindra Majeti Stanford University School of Medicine, Stanford, CA, United States
Liran Shlush
CHIP: Updates and Future Directions
Liran Shlush Weizmann Institute of Science, Rehovot, Israel
Session 6 panel discussion
Session 7: Controversies in AML
Stéphane  de Botton
7+3 or VEN-AZA for complex karyotype AML: 7+3
Stéphane de Botton Gustave Roussy, Paris, France
Daniel  Pollyea
7+3 or VEN-AZA for complex karyotype AML: VEN-AZA
Daniel Pollyea University of Colorado, Denver, CO, United States
7+3 or VEN-AZA panel discussion
Mark Levis
Is it safe to delay initiation of induction? Yes
Mark Levis Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Gunnar Juliusson
Is it safe to delay initiation of induction? No
Gunnar Juliusson Lund University Cancer Centre, Lund, Sweden
Delaying induction panel discussion
Session 8: ASCT and Post-ASCT Maintenance Approaches
Paresh Vyas
Graft-versus-Leukemia biology
Paresh Vyas Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
Christopher  Hourigan
MRD and AML
Christopher Hourigan National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States
Charles Craddock
UK Impact transplant trials
Charles Craddock University of Birmingham, Birmingham, United Kingdom
Alessandro Rambaldi
Optimizing the conditioning regimen in AML
Alessandro Rambaldi University of Milan, Milan, Italy
Victoria Potter
Post-transplant maintenance therapy-where are we?
Victoria Potter King's College Hospital NHS Foundation Trust, London, United Kingdom
John  DiPersio
Novel immunotherapeutic strategies post BMT
John DiPersio Washington University School of Medicine, St. Louis, MO, United States
Session 8 panel discussion
Session 9: MDS New Data/Novel Therapies
Amer Zeidan
Venetoclax and immune checkpoint blockade in MDS
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Valeria  Santini
Imetelstat and roxadustat in MDS
Valeria Santini University of Florence, Florence, Italy
Rami Komrokji
APR-246 and magrolimab in MDS
Rami Komrokji H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Guillermo  Garcia-Manero
Oral HMAs/Pevonedistat in MDS
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 9 panel discussion
Session 10: Mechanisms of Drug Resistance
Catherine Smith
FLT3 inhibitors
Catherine Smith University of California San Francisco, San Francisco, CA, United States
Andrew Wei
Venetoclax
Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia
Amir Fathi
IDHi
Amir Fathi Massachusetts General Hospital Cancer Center, Boston, MA, United States
Roland Walter
Gemtuzumab ozogamicin
Roland Walter Fred Hutchinson Cancer Research Center & University of Washington School of Medicine, Seattle, WA, United States
Session 10 panel discussion
Session 11: To Target or Not in Elderly AML
Naval Daver
FLT3 inhibitors in frontline FLT3 AML ineligible for intensive therapy - Pro
Naval Daver University of Texas MD Anderson Cancer Center, Houston, TX, United States
FLT3 inhibitors panel discussion
Eytan  Stein
HMA-VEN or HMA-IDHi for frontline IDHm elderly AML?
Eytan Stein Memorial Sloan Kettering Cancer Center, New York City, NY, United States
IDHm AML panel discussion
Session 12: Emerging Therapies in AML
Marina Konopleva
Molecular biomarkers and triplets with HMA-VEN
Marina Konopleva University of Texas MD Anderson Cancer Center, Houston, TX, United States
David Sallman
Anti-CD47
David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Eunice  Wang
Menin
Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Stéphane  de Botton
RAR
Stéphane de Botton Gustave Roussy, Paris, France
Gail Roboz
Oral HMA
Gail Roboz Weill Medical College of Cornell University, New York City, NY, United States
Session 12 panel discussion
Session 13: Immunotherapeutics in AML
Ivana Gojo
Understanding immunobiology of AML
Ivana Gojo Johns Hopkins Medicine, Baltimore, MD, United States
Marion Subklewe
BiTES
Marion Subklewe LMU Hospital Munich, Munich, Germany
Joshua Zeidner
Checkpoints
Joshua Zeidner UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NY, United States
Saar  Gill
CAR-T
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
Session 13 panel discussion

Visit the AML channel for the latest updates from leading experts

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter